Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $195.1452W HIGH $269.44
Volume
564.65 K
Value Traded
166.60 M
Short % Float
2.94%
Days to Cover
4.2
+4.59%Week
+10.02%1 Month
+6.3%3 Month
+4.48%6 Month
+13.59%5 Year
+11,848.69%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
22.63 B
EPS (TTM)
8.26
P/E Ratio
28.12
Ent. Value
24.05 B
Total Shares
97.49 M
Float Shares
97.17 M
Insiders
0.34%
Institutions
100.07%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
STE Catalyst Timeline
Dated clinical, regulatory and corporate events for STERIS plc (Ireland)
Past FDA Catalysts and PDUFA Decisions
How STE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
STERIS plc (Ireland) is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every STE program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Sohi MohsenDirector | Option | 4,058 28,363 held | $86.23 | 08/12/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in STE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 1.2 % (-7.7 %) | 7.69 M | 37.31 K | -9.57% ( -3.95 K) |
STE Institutional Ownership Trends
STE Short Interest
Shares sold short, counted twice a month.
2.94%
Short % of Float
of tradable shares sold short
2.9M
Shares Sold Short
+2.5% vs prior count
4.2 Moderate
Days to Cover
trading days of normal volume to buy every short share back
688.4K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How STE ranks across every disease it competes in
Competitive Position is a premium feature
See how STE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSTE News
STESTERIS to Host a Conference Call for Fiscal 2027 Second Quarter on November 5, 2026
STERIS plc announced a conference call to discuss its fiscal 2027 second quarter results. The call is set for November 5, 2026, at 9:00 a.m. ET. A press release with financial details will be issued on November 4, 2026, after market close. A replay of the call will be available later that day.
Read more →STEXodus Medical Announces Agreement to Be Acquired by STERIS (NYSE: STE)
Xodus Medical has announced its acquisition by STERIS, a global leader in healthcare products. This agreement marks a significant milestone for Xodus, enhancing its ability to deliver innovative surgical safety solutions. Both companies share a commitment to patient safety and product excellence, promising to create greater value for customers and opportunities for employees. The partnership aims to leverage complementary capabilities and expand market reach.
Read more →STESTERIS Expands Healthcare Consumables Offering with Definitive Agreement to Acquire Xodus Medical, a Specialty Surgical Products Business Focused on Patient and OR Staff Safety
STERIS plc has announced a definitive agreement to acquire Xodus Medical for $2.1 billion, expected to close by December 31, 2026. This acquisition aims to enhance STERIS's healthcare consumables portfolio, particularly in surgical safety products. The deal is projected to provide significant financial benefits, including cash tax savings and increased revenue.
Read more →STESTERIS to Present at the Morgan Stanley Healthcare Conference
STERIS plc announced its participation in the Morgan Stanley Healthcare Conference scheduled for September 15, 2026. Dan Carestio, the company's President and CEO, will present at 1:05 p.m. Eastern Time. A simultaneous webcast will be available on STERIS's investor relations website, allowing wider access to the presentation.
Read more →STESTERIS Announces Financial Results for Fiscal 2027 First Quarter
STERIS plc reported a 7% increase in revenue for the first quarter of fiscal 2027, totaling $1.5 billion. The company also announced an adjusted EPS of $2.59, indicating strong financial health. However, a targeted restructuring plan was introduced, which may lead to facility closures and significant pre-tax charges. Overall, the company's outlook for the fiscal year remains unchanged.
Read more →STESTERIS To Invest $600 Million to Build a Formulated Chemistries Manufacturing and Distribution Center of Excellence in North Carolina
STERIS plc has announced a $600 million investment to establish a Formulated Chemistries Center of Excellence in North Carolina. This facility will focus on manufacturing and distributing infection prevention and contamination control products for the healthcare and pharmaceutical sectors. The project is expected to create 335 jobs and enhance STERIS's operational capacity in the U.S.
Read more →STESTERIS Raises Dividend to $0.69 per share
STERIS plc announced a quarterly interim dividend of $0.69 per share, marking a $0.06 increase. This increase signifies the company's 21st consecutive year of dividend growth. The dividend will be payable on September 25, 2026, to shareholders recorded by September 4, 2026. The announcement reflects STERIS's ongoing commitment to delivering value to its shareholders.
Read more →STE▲ +5.5%on this newsshared move
STERIS to Host a Conference Call for Fiscal 2027 First Quarter on August 6, 2026
STERIS plc will host a conference call on August 6, 2026, to discuss its fiscal 2027 first quarter results. The call will be accessible via phone and online, with a press release detailing financial results issued the day before. A replay will also be available for those unable to attend live.
Read more →STESTERIS Announces Financial Results for Fiscal 2026 Fourth Quarter and Full Year
STERIS plc reported a strong financial performance for fiscal 2026, with total revenue from continuing operations increasing by 9% to $5.9 billion. The company also announced a new $1 billion share repurchase program, reflecting confidence in its growth. Despite challenges such as tariffs and inflation affecting operating income, adjusted EPS rose to $10.17. Looking ahead, STERIS expects continued revenue growth in fiscal 2027.
Read more →STESTERIS Appoints Pierre Boulud to Board of Directors
STERIS plc has appointed Pierre Boulud to its Board of Directors effective May 5, 2026. Boulud, currently CEO of bioMérieux, brings significant leadership experience and a strong background in the healthcare sector. His appointment is seen as a strategic move to enhance STERIS's operational expertise and global perspective.
Read more →STESTERIS Announces Dividend of $0.63 per share
STERIS plc has declared a quarterly dividend of $0.63 per share, which will be paid on June 26, 2026, to shareholders registered by June 8, 2026. This decision reflects the company's ongoing commitment to providing shareholder value. The announcement supports STERIS's position as a leader in the healthcare industry, focusing on infection prevention. The company also reminded that they may face various risks related to operational and market conditions.
Read more →STESTERIS to Host a Conference Call for Fiscal 2026 Fourth Quarter and Full Year Results on May 12, 2026
STERIS plc will hold a conference call on May 12, 2026, to discuss its fiscal 2026 fourth quarter and full year results. The call is scheduled for 9:00 a.m. ET and will be accessible via phone and online. A press release with financial details will be issued after market close on May 11, 2026.
Read more →STE▼ -7.7%on this news
STERIS Announces Financial Results for Fiscal 2026 Third Quarter
STERIS plc reported a 9% increase in total revenue for its fiscal 2026 third quarter, reaching $1.5 billion. The company also saw a rise in adjusted net income to $249.4 million, driven by strong execution and a diversified portfolio. However, the outlook includes a negative impact from tariffs, estimated to reduce profits. The company maintains its revenue growth expectations for the fiscal year.
Read more →STESTERIS Announces Dividend of $0.63 per share - January 28, 2026
STERIS plc has announced a quarterly dividend of $0.63 per share, payable on March 19, 2026, to shareholders recorded by February 17, 2026. This decision highlights the company's ongoing commitment to providing value to its investors while continuing to focus on patient care and infection prevention. Additional tax information regarding the dividend is available on STERIS's investor relations website.
Read more →STESTERIS to Host a Conference Call for Fiscal 2026 Third Quarter Results on February 5, 2026
STERIS plc has announced a conference call scheduled for February 5, 2026, to discuss its fiscal 2026 third quarter results. The call will be accessible via phone and online, with a press release detailing financial results to be issued the day prior. A replay will also be available for those who cannot attend the live session.
Read more →STE▲ +6.9%on this news
STERIS Announces Financial Results for Fiscal 2026 Second Quarter
STERIS plc reported a 10% increase in total revenue for the second quarter of fiscal 2026, reaching $1.5 billion. Net income also rose to $191.9 million, leading to an improved outlook for the fiscal year. Despite challenges like tariffs and inflation, the company experienced growth across its healthcare and life sciences segments.
Read more →STESTERIS to Host a Conference Call for Fiscal 2026 Second Quarter Results on November 6, 2025
STERIS plc will host a conference call on November 6, 2025, to discuss its fiscal 2026 second quarter results. The call will be accessible via phone and online, with a press release detailing the financial results to be issued the day prior. A replay will also be available for those unable to attend live.
Read more →STE▲ +6.8%on this news
STERIS Announces Chief Financial Officer Transition
STERIS plc announced the transition of its Chief Financial Officer from Michael J. Tokich to Karen L. Burton, effective August 18, 2025. Tokich, who has served as CFO for 17 years, will become a Senior Financial Advisor. Burton, currently the Chief Accounting Officer, has been with STERIS for two decades and is expected to ensure a seamless transition.
Read more →About STERIS plc (Ireland)
Headquarters70 SIR JOHN ROGERSON'S QUAY, DUBLIN, L2, 2
BIOPHARMAWATCH ELITE PLUS
Trade the next STE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime